Expertise in
24
conditions

Dr. Denise Damek

University Physicians Incorporated
Aurora, CO
Expertise in
24
conditions
Specialties:Neurology
Offers Telehealth
Expertise in
24
conditions
OverviewInsuranceLocationsClinical Research

Overview

Denise Damek is a Neurologist in Aurora, Colorado. Dr. Damek is highly rated in 24 conditions, according to our data. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Her clinical research consists of co-authoring 21 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in CO
Hospital Affiliations
University Of Colorado Hospital Authority
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Medica
  •  UnitedHealthcare
  •  Humana

Locations

UNIVERSITY PHYSICIANS INCORPORATED
13123 E 16th Ave, Children's Hospital Colorado, Aurora, CO 80045
720-777-1234

Additional Areas of Focus

Dr. Damek has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Suspended
Publish Date: February 25, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
Enrollment Status: Completed
Publish Date: March 15, 2024
Intervention Type: Drug
Study Drug: Paxalisib (GDC-0084)
Study Phase: Phase 2
Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged Non-small Cell Lung Cancer Patients With Central Nervous System (CNS) Progression After Evidence of Prior CNS Benefit on Relevant Tyrosine Kinase Inhibitors
Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged Non-small Cell Lung Cancer Patients With Central Nervous System (CNS) Progression After Evidence of Prior CNS Benefit on Relevant Tyrosine Kinase Inhibitors
Enrollment Status: Withdrawn
Publish Date: September 21, 2022
Intervention Type: Diagnostic test
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 5 Less Clinical Trials
Similar Doctors
Expertise in
15
conditions
Dr. Kelly G. Knupp
Neurology | Pediatrics | Pediatric Neurology
Expertise in
15
conditions
Dr. Kelly G. Knupp
Neurology | Pediatrics | Pediatric Neurology

University Physicians Incorporated

13123 E 16th Ave, Children's Hospital Colorado, 
Aurora, CO 
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kelly Knupp is a Neurologist and a Pediatrics provider in Aurora, Colorado. Dr. Knupp is highly rated in 15 conditions, according to our data. Her top areas of expertise are West Syndrome, Myoclonic Epilepsy, Spasmus Nutans, and Dravet Syndrome. Dr. Knupp is currently accepting new patients.

Expertise in
20
conditions
Dr. Amanda L. Piquet
Neurology
Expertise in
20
conditions
Dr. Amanda L. Piquet
Neurology

University Physicians Incorporated

1635 Aurora Ct, 
Aurora, CO 
 (0.2 mi)
720-848-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Amanda Piquet is a Neurologist in Aurora, Colorado. Dr. Piquet is highly rated in 20 conditions, according to our data. Her top areas of expertise are Encephalitis, Stiff Person Syndrome, Anti-NMDA Receptor Encephalitis, and Rasmussen Encephalitis. Dr. Piquet is currently accepting new patients.

Expertise in
18
conditions
Dr. Drew S. Kern
Neurology
Expertise in
18
conditions
Dr. Drew S. Kern
Neurology

University Physicians Incorporated

12605 E 16th Ave, Uchealth Anschutz Medical Campus, 
Aurora, CO 
 (0.4 mi)
720-848-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Drew Kern is a Neurologist in Aurora, Colorado. Dr. Kern is highly rated in 18 conditions, according to our data. His top areas of expertise are Parkinson's Disease, Drug Induced Dyskinesia, Essential Tremor, Focal Dystonia, and Deep Brain Stimulation. Dr. Kern is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile